Analyzing BioNano Genomics (BNGO) & PerkinElmer (PKI)

BioNano Genomics (NASDAQ:BNGO) and PerkinElmer (NYSE:PKI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.


This table compares BioNano Genomics and PerkinElmer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNano Genomics N/A N/A N/A
PerkinElmer 4.71% 15.04% 6.35%

Valuation & Earnings

This table compares BioNano Genomics and PerkinElmer’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioNano Genomics $9.50 million 6.87 -$23.36 million N/A N/A
PerkinElmer $2.26 billion 4.13 $292.63 million $2.90 28.88

PerkinElmer has higher revenue and earnings than BioNano Genomics.


PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. BioNano Genomics does not pay a dividend. PerkinElmer pays out 9.7% of its earnings in the form of a dividend.

Insider & Institutional Ownership

80.3% of BioNano Genomics shares are owned by institutional investors. Comparatively, 94.8% of PerkinElmer shares are owned by institutional investors. 2.1% of PerkinElmer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for BioNano Genomics and PerkinElmer, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNano Genomics 0 0 2 0 3.00
PerkinElmer 0 7 3 0 2.30

BioNano Genomics currently has a consensus target price of $12.00, indicating a potential upside of 84.33%. PerkinElmer has a consensus target price of $88.15, indicating a potential upside of 5.24%. Given BioNano Genomics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe BioNano Genomics is more favorable than PerkinElmer.


PerkinElmer beats BioNano Genomics on 9 of the 13 factors compared between the two stocks.

BioNano Genomics Company Profile

BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.

PerkinElmer Company Profile

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with's FREE daily email newsletter.

Leave a Reply